Trial Profile
A Study to Evaluate Immunogenicity and Safety of Boostrix When co-Administered With Fluarix in Subjects 19 Years of Age and Older.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs DTaP vaccine (Primary) ; Influenza virus vaccine (Primary)
- Indications Diphtheria; Influenza virus infections; Pertussis; Tetanus
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline
- 03 Feb 2012 Actual end date (Feb 2007) added as reported by ClinicalTrials.gov.
- 03 Feb 2012 Actual patient number is 1726 according to ClinicalTrials.gov.
- 30 Dec 2011 Results for the exploratory cohort of subjects aged 65 years or older published in Vaccine.